Last updated on April 23, 2014 at 16:13 EDT

Cancer Experts Meet in Boston to Discuss a Promising Approach to Treating the Disease

October 21, 2013

Symposium on the HIF-1a protein and the potential for new medicines targeting it will be held at Harvard Medical School on October 22

CAMBRIDGE, Mass., Oct. 21, 2013 /PRNewswire/ — Academics, healthcare providers, and pharmaceutical industry professionals are gathered in Boston to discuss the latest advances in cancer research. The evening of Tuesday, October 22, those professionals are invited to attend a symposium that will explore one of the most exciting targets in cancer treatment, a protein called hypoxia-inducible factor-1a, or HIF-1a.

The role of HIF-1a in solid tumors has been well documented. It is often present in solid tumors where hypoxic, or low oxygen, conditions are common, and its presence may be increased by anti-angiogenic medicines and radiation. Because HIF-1a can promote resistance, leaders in government, academia, and industry have long sought an effective HIF-1a inhibitor. This week, experts will discuss whether the potential of HIF-1a inhibition is soon to become a reality.

The pre-clinical panel features Giovanni Melillo, MD, of AstraZeneca and formerly of the National Cancer Institute; Sarah Conley, PhD, of MedImmune and formerly of the Max Wicha Lab at the University of Michigan; Amato Giaccia, PhD, of Stanford University; and Robert Kerbel, PhD, of the University of Toronto.

The clinical panel features William Kaelin, MD, of Harvard Medical School; Laura Benjamin, PhD, of Eli Lilly; Mark Dewhirst, DVM, PhD, of Duke University School of Medicine; and Steve Keefe, MD, of the Abramson Cancer Center at the University of Pennsylvania.

Oliver Fetzer, PhD, President and CEO of symposium sponsor, Cerulean Pharma, will welcome attendees, and Robert A. Weinberg, PhD, of the Massachusetts Institute of Technology, will provide closing remarks.

    WHO:       Academics, professionals, and journalists interested in
               the latest research on the HIF-1a protein and the
               advances that illustrate its value as a target for new

    WHAT:      HIF-1a: Ready for Prime Time? includes pre-clinical
               and clinical panels, closing remarks, a poster
               exhibition, and a dinner reception

    WHEN:     Tuesday, October 22, 2013, from 5:30 p.m. to 9:30 p.m.

    WHERE:     Joseph B. Martin Conference Center, Harvard Medical
               School, 77 Avenue Louis Pasteur, Boston, MA 02115

    REGISTER:  Online at www.HIFSymposium.com, via email at
               register@hospicom.us with "HIF Symposium" in the
               subject line, or by phone at 845-265-2155 specifying
               "HIF Symposium"; please note institution, degree, and
               phone number when registering; there is no fee
    --------- -----------------------------------------------------

Media Contact:
Laura Kempke or Kristin Villiotte
Schwartz MSL
+1 781-684-0770

SOURCE Cerulean Pharma

Source: PR Newswire